We warmly invite you to participate in an open, multicenter clinical trial aimed at evaluating the safety and pharmacokinetics, and determining the maximum tolerated and therapeutic dose of three kinase inhibitors: trametinib, gilteritinib or everolimus in combination with dexamethasone in adult oncology patients.